Anxiety, brain fog, and mood changes in midlife patients warranted validation and a structured evaluation that considered ...
Fezolinetant was linked to early improvements in bothersome hot flushes and night sweats. Real-world data showed better ...
Objective sleep data captured by actigraphy in the phase 4 OPTION-VMS study corroborated patient-reported sleep improvements with fezolinetant (Veozah), according to Marla Shapiro ...
Wen Shen, MD, highlights perimenopause as an important period for identifying health risks and supporting healthy aging ...
Wen Shen, MD, describes perimenopause as an opportunity for clinicians to revisit pregnancy-related risk factors and address ...
Soma Mandal, MD, Medical Director, Women's Health, Hackensack Meridian Jersey Shore University Medical Center and Farmingdale, NJ location. Soma Mandal, MD, is launching “Mind, Body, & the Pause: the ...
In recognition of PMOS Awareness Month, Contemporary OB/GYN, Contemporary Pediatrics, and Patient Care Online released a ...
Anita Nelson, MD, discusses the FDA's approval extending etonogestrel implant use to 5 years and the new REMS certification ...
In the debut episode of Missed & Dismissed, Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, talks with Charis Chambers, MD, about ...
A new study identifies hospital factors linked to obstetric unit and hospital closures. Low birth volume and unprofitability were tied to obstetric service loss in a new study. Nearly half of ...
Marla Shapiro, MDCM, explains how OPTION-VMS actigraphy data corroborated patient-reported sleep improvements with fezolinetant (Veozah) as early as week 4.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results